N-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-2-((4-chlorophenyl)thio)acetamide

Catalog No. :
ACDVMZ337
CAS No. :
763124-76-1
Molecular Formula :
C16H13ClN4OS
Molecular Weight :
344.83

IUPAC Name:N-(4-(1H-1,2,4-triazol-1-yl)phenyl)-2-((4-chlorophenyl)thio)acetamide

N-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-2-((4-chlorophenyl)thio)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$323.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-2-((4-chlorophenyl)thio)acetamide
IUPAC NameN-(4-(1H-1,2,4-triazol-1-yl)phenyl)-2-((4-chlorophenyl)thio)acetamide
MDL No.MFCD05155049
Molecular FormulaC16H13ClN4OS
Molecular Weight344.83
SMILESO=C(NC1=CC=C(N2N=CN=C2)C=C1)CSC3=CC=C(Cl)C=C3
InChI KeyUOWOOQRNUYJUGB-UHFFFAOYSA-N
Synonym2-[(4-CHLOROPHENYL)SULFANYL]-N-[4-(1H-1,2,4-TRIAZOL-1-YL)PHENYL]ACETAMIDE;SALOR-INT L447471-1EA;2-((4-CHLOROPHENYL)THIO)-N-(4-(1H-1,2,4-TRIAZOL-1-YL)PHENYL)ACETAMIDE
CAS No.763124-76-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACDVMZ337 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACZQPO601 route compound structure diagram
    ACZQPO6016523-49-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDVMZ337 route product structure diagram
    ACDVMZ337763124-76-1
Inquiry

2. ACDVMZ337 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACZQPO601 route compound structure diagram
    ACZQPO6016523-49-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDVMZ337 route product structure diagram
    ACDVMZ337763124-76-1
Inquiry

Comments (0)